

Marta Bini

Nationality: Italian

WORK EXPERIENCE

[02/01/2024 – Current] **Medical Doctor, Specialized in Medical Oncology**
Gynecologic Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
Country: Italy

EDUCATION AND TRAINING

[09/2011 – 12/07/2017] **Master Degree in Medicine and Surgery**
Università Vita-Salute San Raffaele
City: Milan | **Country:** Italy |

[01/11/2018 – 08/11/2023] **Residency in Medical Oncology**
Università degli Studi di Milano
City: Milano | **Country:** Italy |

[01/03/2022 – 01/09/2022] **Clinical Fellowship in Gynecologic Oncology**
Centre Leon Berard
City: Lyon | **Country:** France |

[01/09/2022 – 08/11/2023] **Residency training in Gynecologic Oncology**
U.O. Ginecologia Oncologica, Istituto Nazionale Tumori
City: Milan | **Country:** Italy |

[08/11/2023] **Graduation Thesis in Gynecologic Oncology**
Università degli Studi di Milano, sede Istituto Nazionale Tumori
City: Milan | **Country:** Italy | | **Final grade:** 110/110 cum laude | **Thesis:** RANDOMIZED PHASE II STUDY ON DECITABINE PLUS CARBOPLATIN VERSUS PHYSICIAN'S CHOICE CHEMOTHERAPY IN RECURRENT, PLATINUM-RESISTANT OVARIAN CANCER

LANGUAGE SKILLS

Mother tongue(s): Italian , French

Other language(s):

English

LISTENING C2 **READING** C2 **WRITING** C2

SPOKEN PRODUCTION C2 **SPOKEN INTERACTION** C2

Levels: A1 and A2: Basic user; B1 and B2: Independent user; C1 and C2: Proficient user

DIGITAL SKILLS

My Digital Skills

Microsoft Office | Microsoft Word

PUBLICATIONS

[2023] **Treatments for rare ovarian tumors: What's new?**

Reference: Bulletin du cancer

Lebreton C, Quesada S, **Bini M**, Babin G, Rossi L, Chopin N, Croce S, Hartog C, Renaud T, Gaillard A, Petit A, Serre A, Trédan O, Rowinski E, Cockenpot V, Treilleux I, Rousset-Jablonski C, Méeus P, Guyon F, Ray-Coquard I

[2023] **Endometrial Carcinosarcoma**

Reference: International Journal of Gynecological Cancer

Bogani G, Ray-Coquard I, Concin N, Ngoi NYL, Morice P, Caruso G, Enomoto T, Takehara K, Denys H, Lorusso D, Coleman R, Vaughan MM, Takano M, Provencher DM, Sagae S, Wimberger P, Póka R, Segev Y, Kim SI, Kim JW, Candido Dos Reis FJ, Ramirez PT, Mariani A, Leitao M, Makker V, Abu-Rustum NR, Vergote I, Zannoni G, Tan D, McCormack M, Paolini B, **Bini M**, Raspagliesi F, Benedetti Panici P, Di Donato V, Muzii L, Colombo N, Pignata S, Scambia G, Monk BJ

[2023] **Update on new treatments for rare ovarian tumors**

Reference: Curr Opin Obstet Gynecol.

Quesada S, **Bini M**, Lebreton C, Ray-Coquard I.

[2022] **Moving HER-2 low breast predictive and prognostic data from clinical trials into the real world**

Reference: Frontiers in Molecular Biosciences

Di Cosimo S, La Rocca E, Ljevar S, De Santis MC, **Bini M**, Cappelletti V, Valenti M, Baili P, de Braud FG, Folli S, Scaperrotta G, Volpi C, Vingiani A, Vernieri C, Verderio P, Miceli R, Pruneri G.

Real-World Data on Newly Diagnosed BRCA-Mutated High-Grade Epithelial Ovarian Cancers: The French National Multicenter ESME Database

Reference: Cancers

Bini M, Quesada S, Meeus P, Rodrigues M, Leblanc E, Floquet A, Pautier P, Marchal F, Provansal M, Campion L, Causeret S, Gourgou S, Ray-Coquard I, Classe JM, Pomel C, De La Motte Rouge T, Barranger E, Savoye AM, Guillemet C, Gladieff L, Demarchi M, Rouzier R, Courtinard C, Romeo C, Joly F.

[2022] **Platinum sensitivity in patients with IDH1/2 mutated vs wild-type intrahepatic cholangiocarcinoma: A propensity score-based study**

Reference: International Journal of Cancer

Niger M, Nichetti F, Casadei-Gardini A, Rizzato MD, Pircher C, **Bini M**, Franza A, Rimini M, Burgio V, Sposetti C, Fornaro L, Rapposelli IG, D'Amico FE, Aprile G, Vivaldi C, Frassinetti GL, Milione M, Leoncini G, Cappetta A, Vasile E, Fassan M, Morano F, Perrone F, Tamborini E, Pruneri G, Lonardi S, Mazzaferro V, Pietrantonio F, Di Bartolomeo M, de Braud F.

[2022] **MGMT inactivation as a new biomarker in patients with advanced biliary tract cancers**

Reference: Molecular Oncology

Niger M, Nichetti F, Casadei-Gardini A, Morano F, Pircher C, Tamborini E, Perrone F, Canale M, Lipka DB, Vingiani A, Agnelli L, Dobberkau A, Hüllein J, Korell F, Heilig CE, Pusceddu S, Corti F, Droz M, Ulivi P, Prisciandaro M, Antista M, **Bini M**, Cattaneo L, Milione M, Glimm H, Köhler BC, Pruneri G, Hübschmann D, Fröhling S, Mazzaferro V, Pietrantonio F, Di Bartolomeo M, de Braud F.

[2023] **BYL719 (alpelisib) for the treatment of PIK3CA-mutated, recurrent/advanced cervical cancer**

Reference: Tumori

Bogani G, Chiappa V, **Bini M**, Ronzulli D, Indini A, Conca E, Raspagliesi F.

[2022] **Clear cell carcinoma of the endometrium**

Reference: Gynecologic Oncology

Bogani G, Ray-Coquard I, Concin N, Ngoi NYL, Morice P, Enomoto T, Takehara K, Denys H, Lorusso D, Coleman R, Vaughan MM, Takano M, Provencher D, Sagae S, Wimberger P, Póka R, Segev Y, Kim SI, Kim JW, Candido Dos Reis FJ, Mariani A, Leitao MM Jr, Makker V, Rustum NA, Vergote I, Zannoni GF, Tan DSP, McCormack M, **Bini M**, Lopez S, Raspagliesi F, Panici PB, di Donato V, Muzii L, Colombo N, Scambia G, Pignata S, Monk BJ.

[2021] **Liquid Biopsy and Radiological Response Predict Outcomes Following Discontinuation of Targeted Therapy in Patients with BRAF Mutated Melanoma.**

Reference: Oncologist

Di Guardo L, Randon G, Corti F, Vallacchi V, Raimondi A, Fucà G, **Bini M**, Maurichi A, Patuzzo R, Gallino G, Mattavelli I, Ruggeri R, Angi M, Cossa M, Valeri B, Cimminiello C, Santinami M, Rivoltini L, de Braud F, Rodolfo M, Vecchio MD.

[2022] **Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology**

Reference: Clin Lung Cancer

Manglaviti S, Brambilla M, Signorelli D, Ferrara R, Lo Russo G, Proto C, Galli G, De Toma A, Occhipinti M, Viscardi G, Beninato T, Zattarin E, **Bini M**, Lobefaro R, Massa G, Bottiglieri A, Apollonio G, Sottotetti E, Di Mauro RM, Trevisan B, Ganzinelli M, Fabbri A, de Braud FGM, Garassino MC, Prelaj A.

[2021] **The Pan-Immune-Inflammation Value in Patients with Metastatic Melanoma Receiving First-Line Therapy**

Reference: Target Oncology

Fucà G, Beninato T, **Bini M**, Mazzeo L, Di Guardo L, Cimminiello C, Randon G, Apollonio G, Bisogno I, Del Vecchio M, Lauria Pantano C, Di Nicola M, de Braud F, Del Vecchio M.

[2021] **Uterine serous carcinosarcoma**

Reference: Gynecologic Oncology

Bogani G, Ray-Coquard I, Concin N, Ngoi NYL, Morice P, Enomoto T, Takehara K, Denys H, Nout RA, Lorusso D, Vaughan MM, **Bini M**, Takano M, Provencher D, Indini A, Sagae S, Wimberger P, Póka R, Segev Y, Kim SI, Candido Dos Reis FJ, Lopez S, Mariani A, Leitao MM Jr, Raspagliesi F, Panici PB, Di Donato V, Muzii L, Colombo N, Scambia G, Pignata S, Monk BJ

[2020] **COVID-19 risk for patients undergoing anticancer treatment at the outpatient clinic of the National Cancer Institute of Milan: The COVINT study**

Reference: Esmo Open

Nichetti F, **Bini M**, Ambrosini M, Ottini A, Rametta A, Leporati R, Polastri D, Pircher C, Dotti K, Ferrari L, de Braud F.

[2023] **Empowering gynecologic oncologists: navigating new drugs and emerging toxicities**

Reference: International Journal of Gynecological Cancer

Mantiero M, **Bini M**, Polignano M, Raspagliesi F, Ducceschi M

[2023] **ESR1 Rearrangement as a Diagnostic and Predictive Biomarker in Uterine Tumor Resembling Ovarian Sex Cord Tumor: A Report of Four Cases**

Reference: JCO Precision Oncology

Bini M, Gantzer J, Dufresne A, Vanacker H, Romeo C, Franceschi T, Treilleux I, Pissaloux D, Tirode F, Blay JY, Ray-Coquard I, Brahmi M.

[2023] **The Revolution of Immunotherapy in Gynecological Cancers: The Lazarus Effect in Endometrial Cancer**

Reference: Journal of Clinical Medecine

Ducceschi, M.; Polignano, M.; **Bini, M.**; Lopez, S.; Conca, E.; Tamborini, E.; Perrone, F.; Carlo Stella, G.; Petrella, M.C.; Carciotto, R; Artioli, G: Maffeis, V; Sartor, L; Raspagliesi, F; Mantiero M

[2023] **Sex dimorphism and cancer immunotherapy: May pregnancy solve the puzzle?**

Reference: Cancer Treat Rev. 2023 Oct 26; PMID: 37918169

Venanzi FM, **Bini M**, Nuccio A, De Toma A, Lambertini M, Ogliari FR, Oresti S, Viganò MG, Brioschi E, Polignano M, Naldini MM, Riva S, Ferrara M, Fogale N, Damiano G, Russo V, Reni M, Veronesi G, Foggetti G, Conforti F, Bulotta A, Ferrara R.

[2023] **High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitors**

Reference: Lung Cancer 2023. PMID : 37918061

Manglaviti S, **Bini M**, Apollonio G, Zecca E, Galli G, Sangaletti S, Labianca A, Sottotetti E, Brambilla M, Occhipinti M, Proto C, Prelaj A, Signorelli D, De Toma A, Viscardi G, Beninato T, Mazzeo L, Bottiglieri A, Leporati R, Fotia G, Ganzinelli M, Portararo P, Garassino MC, de Braud FGM, Lo Russo G, Torri V, Ferrara R.scription...

[2023] **A Ten-years Real-life Experience with Pazopanib in Uterine Leyomiosarcoma in Two High-specialized Centers in Italy: Ef-fectiveness and Safety**

Reference: Cancers.

Mantiero Mara, **Bini Marta**, Polignano Maggie, Luca Porcu, Sanfilippo Roberta, Fabbroni Chiara, Parma Gabriella, Lapresa Mariateresa, Calidona Carmelo, Silvestri Cecilia, Franza Andrea, Raspagliesi Francesco, Nicoletta Colombo, Ducceschi Monika

[2024] **Bridging borders with care: a journey in providing oncology treatment to foreign women at a tertiary center in Italy**

Reference: International Journal of Gynecological Cancer

Mantiero M, **Bini M**, Polignano M, Raspagliesi F, Ducceschi M

[2024] **ESMO Gynaecological Tumours Essentials for Clinicians Second edition**

Chapter : Rare gynaecological cancers

Authors : Ray-Coquard I, **Bini M** & Quesada S